Progressive Multifocal Leukoencephalopathy (PML - JC Virus)

Reactivation of latent JC virus in the setting of profound immunosuppression triggers PML.

Initiation of immunomodulatory drugs such as natalizumab can precipitate viral reactivation.

Progression to AIDS with CD4 count <200 cells/mm³ often precedes PML onset.

Organ transplantation with subsequent immunosuppressive therapy can initiate disease.

Hematologic malignancy treatment causing immune depletion may trigger JC virus activation.

Latency from immunosuppression onset to symptom development ranges from weeks to months.

In HIV patients, PML often develops after several months of advanced immunodeficiency.

After starting natalizumab, PML typically appears within 6 to 24 months of therapy.

Latency can be variable depending on degree and duration of immune compromise.

JC virus remains latent for years before reactivation in susceptible hosts.

Early symptoms are often nonspecific neurological deficits leading to misdiagnosis.

Lack of awareness of PML risk in patients on immunosuppressants delays consideration.

MRI findings may be mistaken for stroke, multiple sclerosis, or lymphoma initially.

CSF PCR for JC virus may be falsely negative early in disease course.

Overlap with other opportunistic infections in immunocompromised patients complicates diagnosis.

Progressive focal neurological deficits including weakness, sensory loss, and visual disturbances are hallmark features.

Cognitive decline with confusion and memory impairment often develops as the disease progresses.

Speech difficulties such as dysarthria or aphasia may be present.

Ataxia and gait instability are common due to cerebellar white matter involvement.

Seizures are less common but can occur in some patients.

Subacute onset of focal neurological deficits such as hemiparesis, visual loss, or aphasia.

Progressive worsening over weeks with symptoms spreading to multiple brain regions.

Cognitive decline and behavioral changes may accompany motor symptoms.

No associated fever or systemic signs of infection typically present.

Symptoms reflect multifocal white matter involvement without mass effect.

History of HIV/AIDS with low CD4 counts or poor antiretroviral adherence.

Use of immunosuppressive medications for autoimmune diseases or malignancies.

Prior organ transplantation requiring chronic immunosuppression.

Hematologic malignancies such as lymphoma or leukemia.

Previous episodes of opportunistic infections indicating severe immunodeficiency.

No known familial or hereditary predisposition to PML has been identified.

No association with inherited demyelinating or immunodeficiency syndromes.

Family history is generally not contributory to risk assessment.

No reported clustering of PML cases within families.

Genetic susceptibility factors remain under investigation but are not established.

Focal neurological deficits such as hemiparesis or visual field defects are common due to demyelination in specific brain regions.

Cognitive impairment including confusion or memory loss may be observed in affected patients.

Ataxia and coordination difficulties result from cerebellar or brainstem involvement.

Aphasia or language disturbances can occur if dominant hemisphere white matter is affected.

Hyperreflexia and other upper motor neuron signs may be present depending on lesion location.

Discontinuation or reduction of immunosuppressive therapy to restore immune function is the primary treatment approach for PML.

Supportive care including physical therapy and symptom management is essential to improve quality of life.

Close monitoring with serial MRI and neurological assessments guides clinical management.